Modeling the Complexity of Drug-Drug Interactions: A Physiologically-based Pharmacokinetic Study of Lenvatinib with Schisantherin A/Schisandrin A

CONCLUSION: Our study developed the first PBPK and DDI models for lenvatinib as a victim drug. STA and SIA slightly increased lenvatinib exposure in simulations, providing clinically valuable information on the safety of concurrent use. Given the minimal pharmacokinetic changes, STA/SIA are unlikely to interact with lenvatinib through pharmacokinetic alterations synergistically but rather may enhance efficacy through inherent anti-cancer efficacy of STA/ SIA.PMID:38556066 | DOI:10.1016/j.ejps.2024.106757
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Source Type: research